Diffuse large B-cell lymphoma with central nervous system relapse: prognosis and risk factors according to retrospective analysis from a single-center experience
Authors:
- 9 April 2009
- journal article
- research article
- Published by Springer Nature in International Journal of Hematology
- Vol. 89 (5) , 577-583
Abstract
The introduction of rituximab for diffuse large B-cell lymphoma (DLBCL) has improved the disease’s overall prognosis. However, relapse in the central nervous system (CNS) is still an issue. We investigated the prognosis and risk factors of CNS recurrence in DLBCL. A total of 403 patients who were diagnosed with DLBCL without CNS involvement between January 1996 and April 2007 at our institution were included in the study. Subsequently, 42 experienced CNS relapse. Clinical information was gathered by chart review. The median disease-free interval to CNS relapse was 625 days. The mean survival periods after relapse in the cases with CNS and extra-CNS involvement were 513 and 1,615 days, respectively (P = 0.0004). Multivariate analysis identified age >60 years (P = 0.031), involvement in two or more extranodal sites (P = 0.040), bone marrow involvement (P = 0.036), an elevated serum lactate dehydrogenase (LDH) level (P = 0.016), and treatment without rituximab before CNS relapse (P = 0.027) as independent predictors of CNS relapse. We have shown that cases of DLBCL occurring in advanced age, involving two or more extranodal sites or the bone marrow, or showing an elevation of LDH have a higher risk of CNS relapse. Rituximab may prevent CNS relapse by reducing the recurrence of DLBCL at all sites. An effective CNS prophylaxis strategy should be determined according to the risk assessment of CNS relapse.Keywords
This publication has 28 references indexed in Scilit:
- Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group reportBlood, 2008
- Effectiveness of second line salvage chemotherapy with ifosfamide, carboplatin, and etoposide in patients with relapsed diffuse large B-cell lymphoma not responding to cis-platinum, cytosine arabinoside, and dexamethasoneLeukemia & Lymphoma, 2007
- The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphomaAnnals of Oncology, 2006
- Central nervous system chemoprophylaxis in non‐Hodgkin lymphoma: current practice in the UKBritish Journal of Haematology, 2005
- Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non‐hodgkin lymphomaCancer, 2002
- Intrathecal Chemotherapy alone is Inadequate Central Nervous System Prophylaxis in Patients with Intermediate-grade Non-Hodgkin's LymphomaLeukemia & Lymphoma, 2002
- Central Nervous System Relapse of Systemic Non-Hodgkin's Lymphoma: Results of Treatment Based on High-dose Methotrexate Combination ChemotherapyLeukemia & Lymphoma, 2002
- Risk Factors for Central Nervous System Involvement in Non-Hodgkins-Lymphoma a multivariate analysisActa Oncologica, 1996
- Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1995
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958